logo
Plus   Neg
Share
Email

AstraZeneca: Lynparza Receives Positive CHMP Opinion For Expanded Indication

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending Lynparza (olaparib) as a 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer, AstraZeneca plc (AZN.L,AZN) stated. Lynparza is currently approved in 64 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless of BRCA status.

Lynparza, which is being jointly developed by AstraZeneca and MSD or Merck & Co., Inc., is approved for advanced ovarian cancer and metastatic breast cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
DMM Vission is recalling five lots of Cleaner Hand Sanitizer due to potential presence of methanol (wood alcohol), the U.S. Food & Drug Administration said in a statement. The company is yet to receive any reports of adverse events involving the product. Facebook Inc. said it will ban ads that seek to delegitimize the Presidential election. The announcement is in line with the social media giant's decision to prohibit ads that make premature declarations of victory as it aims to protect the integrity of the upcoming U.S. 2020 elections. Rob Leathern, Director of Product Management, in a tweet said that these changes apply to ads across Facebook... While reporting financial results for the first quarter of fiscal 2021 on Thursday, Conagra Brands, Inc. (CAG) provided only its adjusted earnings and organic net sales growth guidance for the second quarter of fiscal 2021. The company is still not initiating annual outlook, as is usual, as the impact...
Follow RTT